Incyte (INCY) is a publicly traded Healthcare sector company. As of October 3, 2026, INCY trades at $115.62 with a market cap of $23.74B and a P/E ratio of 43.18. INCY moved -1.58% today. Year to date, INCY is +13.69%; over the trailing twelve months it is +33.63%. Its 52-week range spans $53.56 to $132.60. Analyst consensus is buy with an average price target of $130.79. Rallies surfaces INCY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Incyte Corporation: H.C. Wainwright raises target price to $152 from $150: H.C. Wainwright raised its target price for Incyte to $152 from $150.
| Metric | Value |
|---|---|
| Price | $115.62 |
| Market Cap | $23.74B |
| P/E Ratio | 43.18 |
| EPS | $2.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $132.60 |
| 52-Week Low | $53.56 |
| Volume | 1.70M |
| Avg Volume | 0 |
| Revenue (TTM) | $3.70B |
| Net Income | $597.60M |
| Gross Margin | 93.10% |
21 analysts cover INCY: 0 strong buy, 11 buy, 10 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $130.79.